Our mission is to bring awareness and innovation to finding a cure for ALS, also know as Lou Gehrig’s Disease. We imagine a world where ALS is a treatable, manageable illness rather than an underfunded, terminal disease that devastates the lives of individuals and their families every 90 minutes.
ALS or Lou Gehrig’s disease is a rapidly progressive and ultimately fatal disease. There is no known cure, and the few treatment options that do exist are only able to extend life a relatively short period of time. Death often occurs within 4 to 6 years of diagnosis.
The laboratory of Dr. Stanley Appel, director of The Methodist Neurological Institute, has been a pioneer in documenting the importance of the immune system in modulating ALS disease progression in both animal models and in humans. Animal models in early stages of the disease have demonstrated that protective immunity leads to slower disease progression, while in later stages of disease, cytotoxic immunity leads to accelerated disease progression. We have recently had considerable success in defining the immune signals that mediate differing rates of disease progression in these models.